BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang CJ, Dagan R, Tamms GM, Sterling T, Morgan L, Shi Y, Pedley A, Musey LK, Buchwald UK. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). Vaccine 2021:S0264-410X(21)01097-5. [PMID: 34507861 DOI: 10.1016/j.vaccine.2021.08.049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Pan LL, Gao Z, Zhou WW, Li MJ, Fang WJ, Ji WJ, Zhao Y, Du L, Zhao YL. Safety of the 15-valent pneumococcal conjugate vaccine: A phase I clinical trial. Hum Vaccin Immunother 2022;:2116881. [PMID: 36121914 DOI: 10.1080/21645515.2022.2116881] [Reference Citation Analysis]
2 Deng JZ, Lin J, Chen M, Lancaster C, Zhuang P. Characterization of High Molecular Weight Pneumococcal Conjugate by SEC-MALS and AF4-MALS. Polymers 2022;14:3769. [DOI: 10.3390/polym14183769] [Reference Citation Analysis]
3 Kishino H, Sawata M, Igarashi R, Shirakawa M, Pedley A, Musey L, Platt HL, Buchwald UK. Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared With 13- valent Pneumococcal Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE). Jpn J Infect Dis 2022. [PMID: 35908869 DOI: 10.7883/yoken.JJID.2022.060] [Reference Citation Analysis]
4 Passaris I, Mauder N, Kostrzewa M, Burckhardt I, Zimmermann S, van Sorge NM, Slotved HC, Desmet S, Ceyssens PJ. Validation of Fourier Transform Infrared Spectroscopy for Serotyping of Streptococcus pneumoniae. J Clin Microbiol 2022;:e0032522. [PMID: 35699436 DOI: 10.1128/jcm.00325-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kay EJ, Mauri M, Willcocks SJ, Scott TA, Cuccui J, Wren BW. Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines. Microb Cell Fact 2022;21:66. [PMID: 35449016 DOI: 10.1186/s12934-022-01792-7] [Reference Citation Analysis]
6 Deb A, Guggisberg P, Mutschler T, Owusu-Edusei K, Bencina G, Johnson KD, Ignacio T, Mathijssen D, Qendri V. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. Expert Rev Vaccines 2022. [PMID: 35220875 DOI: 10.1080/14760584.2022.2046468] [Reference Citation Analysis]
7 Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, Poehling KA, Pilishvili T. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:109-17. [PMID: 35085226 DOI: 10.15585/mmwr.mm7104a1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]